Dec. 23 at 5:30 PM
$PLX Interesting article detailing the recent Amicus acquisition by BioMarin.
https://www.lqventures.com/lucid-diligence-brief-biomarin-to-acquire-amicus-therapeutics-for-4-8b/?utm_source=dlvr.it&utm_medium=threads&amp
There are still some hurdles before the deal can be approved. They also have to get approvals from the EU Commission where Galafold generates significant revenue.
Post-deal the article calls out the risk if BioMarin shifts resources away from Galafold marketing or integration falters, this could exacerbate volume stagnation. Galafold's growth could plateau if competing therapies continue to gain traction like Elfabrio and Fabrazyme, which target broader Fabry patient population. BioMarin is also taking on a huge debt load (~
$3.7B) to fund the deal which is a pretty big strain on their balance sheet and it will be interesting to see if it limits R&D investments in Galafold expansions or force cost-cutting of Fabry-related resources.
Will be interesting to follow Galafold’s sales after the acquisition to see how it plays out.
